1. Home
  2. SNGX vs BYAH Comparison

SNGX vs BYAH Comparison

Compare SNGX & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.37

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Park Ha Biological Technology Co. Ltd. Ordinary Shares

BYAH

Park Ha Biological Technology Co. Ltd. Ordinary Shares

N/A

Current Price

$0.57

Market Cap

5.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
BYAH
Founded
1987
2016
Country
United States
China
Employees
N/A
40
Industry
Biotechnology: Pharmaceutical Preparations
Package Goods/Cosmetics
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.0M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
SNGX
BYAH
Price
$0.37
$0.57
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
608.4K
5.8M
Earning Date
05-08-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
N/A
EPS
N/A
N/A
Revenue
$119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.05
52 Week High
$6.23
$6.49

Technical Indicators

Market Signals
Indicator
SNGX
BYAH
Relative Strength Index (RSI) 37.48 35.75
Support Level $0.28 $0.14
Resistance Level $0.41 $1.34
Average True Range (ATR) 0.02 0.17
MACD 0.01 -0.07
Stochastic Oscillator 15.68 7.47

Price Performance

Historical Comparison
SNGX
BYAH

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.

Share on Social Networks: